Community-reported effects include nausea, dizziness, and vivid dreams
In a 10-week clinical trial, a daily dose of 20 mg oral semaglutide achieved a steady-state plasma concentration of 30 nM, and when daily dose of oral semaglutide was increased to 40 mg, the semaglutide plasma concentration reached about 60 nM (102), which was over a thousand times higher than the EC50 of semaglutide for GLP-1R activation (95)
Optimized Protocol for Selective Fat Metabolism Dosing: Starting dose: 250 mcg per day (subcutaneous injection) Standard dose: 300-500 mcg per day after 1-2 weeks Frequency: Once daily or divided into two doses (morning and early afternoon) Administration: Route: Subcutaneous injection (abdomen, thigh, or upper arm) Timing: Morning fasted state ideal, or 30-60 minutes before cardio Storage: Reconstituted peptide refrigerated, typically stable 30-60 days Cycle Length: 12-16 weeks for initial assessment, with potential for extended protocols based on clinical trial data showing safe use up to 24 weeks
Most side effects diminish over time with proper dosage adjustments under medical supervision
